Better tools. Better news.
Sunday, November 22, 2026 · UTC
World

Daraxonrasib shows 42% response rate in pretreated RAS-mutant NSCLC in phase 1/2 trial

Daraxonrasib achieved 42% response rate in pretreated RAS-mutant NSCLC patients in an MD Anderson-led trial.

TruthFoundry News Desk
References:
Updated
Share on X
Stands on 7 placed sources from 2 publishers.
A phase 1/2 trial led by The University of Texas MD Anderson Cancer Center and published in the New England Journal of Medicine on 2026-09-02 evaluated the oral RAS inhibitor daraxonrasib in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC). [1] In a subgroup of docetaxel-naive patients who had previously received platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy, daraxonrasib showed a confirmed objective response rate of 42%, a median progression-free survival of 8.3 months, and a median overall survival of 16 months. [2][7] The oral RAS inhibitor daraxonrasib (brand name Rasonque) recently received FDA approval for metastatic pancreatic ductal adenocarcinoma. [3] At the recommended phase 3 dose, 51% of patients experienced an adverse effect at grade 3 or higher, 71% had dose modifications, and 10% discontinued treatment; rash occurred in 90% of patients (8% grade 3 or higher) and gastrointestinal issues including diarrhea (73%), nausea (62%), and vomiting (54%) each occurred in less than 10% at grade 3 or higher. [4][6] David Hong, deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead, said the early results are encouraging because the few treatment options for these patients, such as docetaxel, often have modest benefit and substantial toxicities. [5]
Proof7 sources · 2 publishers
What this stands on
  1. A phase 1/2 trial led by The University of Texas MD Anderson Cancer Center and published in the New England Journal of Medicine on 2026-09-02 evaluated the oral RAS inhibitor daraxonrasib in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC). · Medical Xpress
  2. The trial reported that among 38 patients with NSCLC treated with 160-220 mg of daraxonrasib, the objective response rate was 42%, median duration of response was 11.5 months, median progression-free survival was 8.3 months, and median overall survival was 16 months. · Medical Xpress
  3. The oral RAS inhibitor daraxonrasib (brand name Rasonque) recently received FDA approval for metastatic pancreatic ductal adenocarcinoma. · MedpageToday
  4. At the recommended phase 3 dose, 51% of patients experienced an adverse effect at grade 3 or higher, 71% had dose modifications, and 10% discontinued treatment; rash occurred in 90% of patients (8% grade 3 or higher) and gastrointestinal issues including diarrhea (73%), nausea (62%), and vomiting (54%) each occurred in less than 10% at grade 3 or higher. · Medical Xpress
  5. David Hong, deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead, said the early results are encouraging because the few treatment options for these patients, such as docetaxel, often have modest benefit and substantial toxicities. · Medical Xpress
  6. Grade 3 or higher adverse events occurred in 54% of patients in the trial, with pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%) occurring in at least 5% of patients. · MedpageToday
  7. In a subgroup of docetaxel-naive patients who had previously received platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy, daraxonrasib showed a confirmed objective response rate of 42%, a median progression-free survival of 8.3 months, and a median overall survival of 16 months. · MedpageToday
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · 7 sources · v 002The worldThe recordThe writingThe filing

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Thursday, September 3, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.
Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.
Integrity
Content hash (SHA-256)89db768618279b2ef825c0705f42de91b64847475a34f2b772b6200312584342
Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed
Receiptthis revision predates receipt-keeping; the filed row lives on the record
Machine readablethe full proof, JSON
Verify

A signature proves who filed this and that it has not changed since. It never makes a claim true.